Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(412):252–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–32.

Article  CAS  PubMed  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. Faculty Sci Med Health - Papers: Part B. 2019;37:537.

CAS  Google Scholar 

Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.

Article  PubMed  PubMed Central  Google Scholar 

Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19:1579–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71:1755–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904–11.

Article  PubMed  Google Scholar 

Yousif LI, Tanja AA, de Boer RA, Teske AJ, Meijers WC. The role of immune checkpoints in cardiovascular disease. Front Pharmacol. 2022;13:4065.

Article  Google Scholar 

Choudhary A, Brinkley DM, Besharati S, et al. PD-L1 (programmed death ligand 1) as a marker of acute cellular rejection after heart transplantation. Circ Heart Fail. 2021;14:E008563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma X, Zhang Y, Wang S, Wei H, Yu J. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: a systematic review. J Cancer. 2021;12:1318.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 2018;24:47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Rubio-Infante N, Ramírez-Flores YA, Castillo EC, Lozano O, García-Rivas G, Torre-Amione G. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. Eur J Heart Fail. 2021;23:1739–47. This meta-analysis highlights the increased incidence of ICI-mediated cardiotoxicity as a result of dual ICI therapy or combining ICI therapy with other anti-cancer treatments.

Article  CAS  PubMed  Google Scholar 

Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.

Article  PubMed  PubMed Central  Google Scholar 

Okazaki T, Okazaki IM, Wang J, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208:395.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–27.

Article  CAS  PubMed  Google Scholar 

•• Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med. 2022;386:24–34. This phase 2–3 clinical trial demonstrated, for the first time, the synergtistic anti-tumor activity of combined nivolumab and relatlimab, the first-in-class human LAG-3 inhibitor. Myocarditis incidence was nearly threefold in the combined group compared to the nivolumab monotherapy group, resulting in one death.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gong J, Drobni ZD, Zafar A, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e002771.

Article  PubMed  PubMed Central  Google Scholar 

Cozma A, Sporis ND, Lazar AL, et al. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Int J Mol Sci. 2022;23:10948.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oishi H, Morimoto R, Shimoyama Y, Kuroda K, Urata T, Kondo T, Okumura T, Bando YK, Akiyama M, Murohara T. Myocardial vasculitis associated with the immune checkpoint inhibitor pembrolizumab. JACC Case Rep. 2020;2:1937.

Article  PubMed  PubMed Central  Google Scholar 

Ma Z, Pei J, Sun X, Liu L, Lu W, Guo Q, Lyu J, Liu Y, Zhang Y, Zhao Z. Pericardial toxicities associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system (FAERS) database. Front Pharmacol. 2021. https://doi.org/10.3389/FPHAR.2021.663088/PDF.

Article  PubMed  PubMed Central  Google Scholar 

Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, Lyon AR, Padera RF, Johnson DB, Moslehi J. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115:854–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mao S, Zhou F, Liu Y, et al. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC. Cancer Immunol Immunother. 2022;71:219–28.

Article  CAS  PubMed  Google Scholar 

Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med. 2018;379:2040–51.

Article  CAS  PubMed  Google Scholar 

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895–903.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Taniguchi Y, Shimokawa T, Takiguchi Y, et al. A randomized comparison of nivolumab versus nivolumab + docetaxel for previously treated advanced or recurrent ICI-naïve non-small-cell lung cancer: TORG1630. Clin Cancer Res. 2022;28:4402–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du S, Zhou L, Alexander GS, et al. PD-1 modulates radiation-induced cardiac toxicity through cytotoxic T lymphocytes. J Thorac Oncol. 2018;13:510–20.

Article  CAS  PubMed  Google Scholar 

Myers CJ, Lu B. Decreased survival after combining thoracic irradiation and an anti-PD-1 antibody is correlated with increased T cell infiltration into cardiac and lung tissues. Int J Radiat Oncol Biol Phys. 2017;99:1129.

Article  PubMed  PubMed Central  Google Scholar 

Meijers WC, Moslehi JJ. Need for multidisciplinary research and data-driven guidelines for the cardiovascular care of patients with cancer. JAMA. 2019;322:1775–6.

Article  PubMed  PubMed Central  Google Scholar 

Zhang XT, Ge N, Xiang ZJ, Liu T. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell Int. 2022;22:1–12.

Article  Google Scholar 

Bishnoi R, Shah C, Blaes A, Bian J, Hong Y-R. Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: a SEER-medicare study CVD outcomes with the use of ICI in mNSCLC. Lung Cancer. 2020;150:172–7.

Article  PubMed  Google Scholar 

Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA, Burkhart K, Lee P, Patel SP, Abagyan R. Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Scientific Reports. 2021;11(1):1–15.

Article  Google Scholar 

Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115:844–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Motzer RJ, Penkov